Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q3 FY26 Earnings Presentation
17 slides from Dr. Reddy's Laboratories's earnings presentation, Jan 21, 2026
Slide 1: Q3FY26 Results Update
E & (2 es 2) 2) 3 Dr. Reddy’s Q3FY26 RESULTS UPDATE
Slide 2: Safe Harbor Statement
Safe Harbor Statement Dr.Reddy’s @ This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying ass
Slide 3: Q3FY26 Financial Highlights
Q3FY26 Financial Highlights Dr.Reddy’s @¥ Double-digit growth in base business‘; overall steady profitability, despite product specific headwinds Revenues 28,727 cr PB 4.4nyvoy ¥ 0.9%Q00 One-time provision Impact of new Labour Codes in India UNDERLYING FINANCIALS (Adjusted for One-off) EBITDA | EBIT
Slide 4: Business Highlights
Q3FY26 Business Highlights Dr.Reddy’s @ Continued progress on strategic priorities + Strategic collaboration with Immutep for commercialisation of a novel, immunotherapy oncology drug, Immu tep Empowering the Immune System tL Eftilagimod Alfa, in key Emerging Markets. + Launched Hevaxin®, a novel, r
Slide 5: Other Highlights
Q3FY26 Other Highlights ESG Announced Science-Based Net Zero Climate Targets - only Indian Pharma co to commit to such a target by FY2045. Leadership position in 2025 CDP Water Security & Climate Change. Cll Award of Merit for Excellence in 4R category, amongst top 25 in India. TUV SUD South Asia ce
Slide 6: Revenue Split
Q3FY26 Revenue Split Dr.Reddy’s Qi Broad-based growth, aided by forex; moderated by product-specific headwinds in the US REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS | 22,964 cr 21,448 cr 91% ——— a Overall : SB r2~yor F 9%G0a » | Ty PB ro%voy # sxa0a °% 17% 28,727 cr
Slide 7: Key Financial Metrics
Key Financial Metrics Sustaining growth & profitability, while investing for the future REVENUES (& Cr) QS’ 26 i 8, Q2FY26 QUFY26 8,545 Q4Fy25 8,506 Q3FY25 8,359 DILUTED EPS @) 727 8,805 Q3FY26 i 14.5 Q2FY26 Qt1FY26 Q4FY25 Q3FY25 17.3 17.0 19.1 16.9 GROSS MARGINS (% of Revenues) Q3FY26 MEM 53.6% Q2F
Slide 8: North America Performance
Q3FY26 North America Performance Dr.Reddy's Qi Moderated due to lower Lenalidomide sales and continued pricing pressure MARKET PERFORMANCE KEY UPDATES >) 2.6% vs -0.3% DRL 6% vs Genesee % + First-to-market launch of Olopatadine Hydrochloride we einen Ophthalmic Solution, in the US NEW LAUNCHES Reven
Slide 9: India Performance
Q3FY26 India Performance Dr.Reddy’s @ Robust double-digit growth, continued outperformance of IPM ~ MARKET PERFORMANCE“ KEY UPDATES 18% 12.3% vs 11.9% ADRL MQT Growth vs IPM (Dec’25) + Launched Hevaxin®, a novel, recombinant vaccine for : IPM RANK prevention of Hepatitis-E virus infection. Revenues
Slide 10: Emerging Markets Performance
Q3FY26 Emerging Markets Performance Dr.Reddy's @ New product launches & favourable forex driving growth KEY UPDATES 22% COUNTRIES PRESENT IN 48 + Collaboration with Immutep for commercialisation of novel, immunotherapy oncology drug, Eftilagimod Alfa, outside; 3 Py oncology ones immutep North Americ
Slide 11: Europe Performance
Q3FY26 Europe Performance Dr.Reddy’s Qi Momentum in NRT business, new launches, aided by forex tailwinds » 17% Revenues 21,448 cr BP 20%YoY 5%Q00 Growth Drivers : Acquired NRT business (now in base), new product launches, favourable forex, offset by price erosion Historical Revenues (% Cr) QSFY26 DE
Slide 12: PSAI Performance
Q3FY26 PSAI Performance Dr.Reddy's Qi Adverse Product mix impacting gross margins LZ KEY UPDATES 9% GROSS MARGIN + Non-binding strategic cooperation term sheet signed Occhio bs with Hybio Pharmaceutical on Peptide APIs. 17.3% vs 28.6% Q3FY26 vs Q3FY25 Revenues + Aurigene Pharmaceutical Services Limi
Slide 13: In Summary
In Summary Dr.Reddy's @* A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS © ADVANCE KEY PIPELINE PRODUCTS (SEMAGLUTIDE, ABATACEPT) © DRIVE EFFICIENCIES THROUGH BETTER OPERATIONAL LEVERAGE Dr.Reddy ‘ AUGMENT ORGANIC GROWTH WITH M&A AND IN-LICENSING © STRE
Slide 14: At a glance
At a glance Dr.Reddy’s @: ° We accelerate access to affordable and innovative medicines because Good Health Can’t Wait. ~756mn patients reached globally $3.8bn Revenue 17% Revenue Growth 28% EBITDA Margin ~28% Roce 26,000+ Employees globally 57 Nationalities (Employees) 83 Markets served 32 Plants (
Slide 15: Consolidated Income Statement
Consolidated Income Statement Particulars (& Cr) Revenues Cost of Revenues Gross Profit % of Revenues Selling, General & Administrative Expenses : % of Revenues Research & Development Expenses % of Revenues Impairment of Non-Current Assets, net ~ Other (Incomey/Expense, net Finance (Income)/Expense,
Slide 16: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 17: Good Health Can't Wait
DR Reddys Laboratories — Q3 FY26 Earnings Presentation on 6ix